Get an in-depth insight of one of the leading biotech investors
«Healthcare markets rebounded from the April sell-off to close the second quarter in positive territory»
Dr. Erich Hunziker
Interview Head Investment Team
The corona pandemic continues to hold the world in its grip. The biotech industry, on the other hand, is additionally moved by a new drug, the Alzheimer's drug Aduhelm from Biogen. A few weeks ago, this drug received FDA approval in June of this year. Find out more in a conversation with Dr. Daniel Koller, Head Investment Team, on the occasion of the half-year figures of BB Biotech AG 2021.
BB Biotech invests in fast-growing biotechnology companies that are developing and marketing innovative drugs. It focuses on biotech companies whose products address areas of significant unmet medical needs and thus have above-average sales and profit-growth potential.